rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors

Background Chimeric antigen receptor T-cell (CAR-T) therapy has achieved remarkable remission in patients with B-cell malignancies. However, its efficacy in treating solid tumors remains limited. Here, we investigated a combination therapy approach using an engineered long-acting interleukin (IL)-7...

Full description

Bibliographic Details

Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Dan li, Mitchell Ho, Byung Ha Lee, Sara Ferrando-Martinez, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-07-01
Online Access:	https://jitc.bmj.com/content/12/7/e008989.full